logo
Video: World War I submarine found off San Diego coast

Video: World War I submarine found off San Diego coast

The USS F-1, a World War I-era U.S. Navy submarine, was recently discovered by researchers off the cost of San Diego, California. The discovery comes 108 years after the submarine was 'lost at sea' in a training accident in December of 1917.
In a recent press release, Woods Hole Oceanographic Institution (WHOI) announced, 'A deep-sea training and engineering dive off the coast of San Diego provided an opportunity for never-before-seen imagery of the U.S. Navy submarine USS F-1, lost at sea in an accident on December 17, 1917, that resulted in the death of 19 crew members.'
According to the press release, WHOI researchers captured images of the World War I-era Navy submarine by using 'Sentry,' an autonomous underwater vehicle, and 'Alvin,' a human-occupied vehicle, to access the remains of the submarine located under more than 1,300 feet of water.
'Advanced ocean technology and simple teamwork played a big part in delivering these new images,' Bruce Strickrott, manager of the Alvin Group at WHOI and the senior pilot who helped lead the recent expedition, said. 'Once we identified the wreck and determined it was safe to dive, we were able to capture never-before-seen perspectives of the sub. As a U.S. Navy veteran, it was a profound honor to visit the wreck of the F-1 with our ONR and NHHC colleagues aboard Alvin.'
READ MORE: Pics: Surprising WWII shipwreck finds revealed
WHOI explained that the recent expedition was part of a training and engineering mission intended to give pilots of the underwater submersibles an opportunity to increase their piloting skills and develop technology for underwater research.
'It was an incredibly exciting and humbling experience to visit these historically significant wrecks and to honor the sacrifice of these brave American Sailors,' Naval History and Heritage Command (NHHC) Underwater Archaeologist Brad Krueger said. 'All of us at the NHHC are grateful for this collaboration, which also enabled us to document and assess the condition of the crafts.'
According to the press release, the crew on the Atlantis, which was stationed above the location of the remains of the USS F-1, held a remembrance ceremony in honor of the 19 Navy members who were killed in the training incident in 1917.
'History and archaeology are all about people and we felt it was important to read their names aloud,' Krueger stated. 'The Navy has a solemn responsibility to ensure the legacies of its lost Sailors are remembered.'
A video shared on X, formerly Twitter, by WHOI shows the new footage of the USS F-1 submarine as well as part of the ceremony held in honor of the 19 Navy members.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

BioMarin's ROCTAVIAN Shows Sustained Efficacy, Safety Over 5 Years for Severe Hemophilia A
BioMarin's ROCTAVIAN Shows Sustained Efficacy, Safety Over 5 Years for Severe Hemophilia A

Yahoo

timea day ago

  • Yahoo

BioMarin's ROCTAVIAN Shows Sustained Efficacy, Safety Over 5 Years for Severe Hemophilia A

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the most undervalued US stocks according to analysts. On June 24, BioMarin Pharmaceutical Inc. presented new 5-year data from its Phase 3 GENEr8-1 trial at the 33rd Congress of the International Society on Thrombosis and Haemostasis/ISTH in Washington, D.C., which took place from June 21 to 25. The data reinforced the long-term efficacy and safety of ROCTAVIAN (valoctocogene roxaparvovec-rvox) as a gene therapy for severe hemophilia A. The GENEr8-1 trial is the longest and largest hemophilia gene therapy study to date, and demonstrated sustained Factor VIII (FVIII) expression and durable bleed control 5 years after a single treatment with ROCTAVIAN. A pharmaceutical plant manufacturing a proprietary synthetic oral form of a C-type natriuretic peptide. FVIII activity remained consistent with previously reported results. Importantly, no new safety signals were observed over the 5-year study period. Across all 134 participants who received ROCTAVIAN in the study, there were no cases of FVIII inhibitors or thromboembolic events, and no treatment-related malignancies were observed. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is a biotechnology company that develops and commercializes therapies for life-threatening rare diseases and medical conditions internationally. While we acknowledge the potential of BMRN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio

Metabolics Pharma Announces ENT-03 Generates Sustained Weight Loss and Liver Pathology Improvements in an Animal Model for Obesity
Metabolics Pharma Announces ENT-03 Generates Sustained Weight Loss and Liver Pathology Improvements in an Animal Model for Obesity

Yahoo

time2 days ago

  • Yahoo

Metabolics Pharma Announces ENT-03 Generates Sustained Weight Loss and Liver Pathology Improvements in an Animal Model for Obesity

DOYLESTOWN, Pa., June 27, 2025--(BUSINESS WIRE)--Metabolics Pharma ("Metabolics"), a privately held, Doylestown-based, clinical-stage biopharmaceutical company pioneering novel treatments for metabolic diseases, today announced that its drug candidate, ENT-03, showed significant benefit in metabolic dysfunction in addition to sustaining weight loss, improvement in blood glucose, and insulin sensitivity in comparison to semaglutide in an animal model for obesity. "Metabolics Pharma spun off from its parent company, Enterin, in late 2024 so that the company could focus its efforts on and enhance the value of its lead asset, ENT-03, for the treatment of obesity and certain comorbidities," said Richard Larson, M.D., Ph.D., Chief Executive Officer, Chief Medical Officer and Board Chairman of Metabolics Pharma. "These preclinical data highlight both the promise and potential value of ENT-03 in the treatment of metabolic disease. The research shows that ENT-03 clearly improves insulin sensitivity and sustained weight reduction that persists following cessation of treatment. This research is the foundation for our Phase 1 clinical trials in healthy obese and diabetic obese subjects." ENT-03 is a novel, centrally acting aminosterol with Protein Tyrosine Phosphatase 1B (PTP1B) inhibitory activity, which normalizes glucose and causes weight loss by acting on brain circuits that regulate energy and metabolism. In obese, diabetic mice, ENT-03 rapidly lowers blood glucose, reduces food intake and adiposity, eliminates liver fat, and improves liver function. This study compared ENT-03 to semaglutide, a combination of the two compounds, and vehicle in Diet Induced Obesity (DIO) mice. While the vehicle-treated mice gained weight through the duration of the study, mice treated with ENT-03, Semaglutide, or a combination of the two drugs all lost weight and reduced insulin and glucose levels. ENT-03 showed a greater reduction in weight than Semaglutide over the 10-week treatment period. Additive weigh loss was seen when the drugs were used in combination. After cessation of therapy, weight loss and reduction in glucose and insulin were sustained for an additional two months in the ENT-03 treated mice but not Semaglutide treated mice. In addition, ENT-03 showed substantially greater preservation of lean mass in comparison to other treatment groups. "GLP-1 agonists have revolutionized the treatment of obesity and type 2 diabetes," said Richard Larson, MD, PhD. "However, their impressive efficacy comes at the price of tolerability challenges, the loss of lean body mass, and the need to remain on treatment to sustain weight loss. ENT-03 represents a novel drug candidate that could be an alternative treatment to GLP-1 agonists or used in combination with them. We believe that ENT-03 could have a substantial impact on the obesity drug market since it has potential benefits beyond weight loss." Metabolics Pharma has completed a Phase 1a, first in human, randomized, double-blind, single ascending dose study of ENT-03. Results of the Phase 1a trial were presented at the American Diabetes Association 85th Scientific Sessions on June 22, 2025. A Phase 1b clinical trial is planned to initiate in the second half of 2025. About Metabolics Pharma Metabolics Pharma develops novel therapies for the treatment of metabolic diseases including obesity and type 2 diabetes. The Company's lead compound, ENT-03, in development for the treatment of type 2 diabetes and obesity, increases insulin sensitivity by acting at the level of the brain. ENT-03 has completed a Phase 1a clinical trial and will begin a Phase 1b clinical trial in the second half of 2025. For more information, please visit View source version on Contacts Richard Larson, M.D., Executive Officer, Chief Medical Officer, and Chairman of the Board John DessoukiChief Financial Sign in to access your portfolio

Metabolics Pharma Announces ENT-03 Generates Sustained Weight Loss and Liver Pathology Improvements in an Animal Model for Obesity
Metabolics Pharma Announces ENT-03 Generates Sustained Weight Loss and Liver Pathology Improvements in an Animal Model for Obesity

Business Wire

time2 days ago

  • Business Wire

Metabolics Pharma Announces ENT-03 Generates Sustained Weight Loss and Liver Pathology Improvements in an Animal Model for Obesity

DOYLESTOWN, Pa.--(BUSINESS WIRE)--Metabolics Pharma ('Metabolics'), a privately held, Doylestown-based, clinical-stage biopharmaceutical company pioneering novel treatments for metabolic diseases, today announced that its drug candidate, ENT-03, showed significant benefit in metabolic dysfunction in addition to sustaining weight loss, improvement in blood glucose, and insulin sensitivity in comparison to semaglutide in an animal model for obesity. 'Metabolics Pharma spun off from its parent company, Enterin, in late 2024 so that the company could focus its efforts on and enhance the value of its lead asset, ENT-03, for the treatment of obesity and certain comorbidities,' said Richard Larson, M.D., Ph.D., Chief Executive Officer, Chief Medical Officer and Board Chairman of Metabolics Pharma. 'These preclinical data highlight both the promise and potential value of ENT-03 in the treatment of metabolic disease. The research shows that ENT-03 clearly improves insulin sensitivity and sustained weight reduction that persists following cessation of treatment. This research is the foundation for our Phase 1 clinical trials in healthy obese and diabetic obese subjects.' ENT-03 is a novel, centrally acting aminosterol with Protein Tyrosine Phosphatase 1B (PTP1B) inhibitory activity, which normalizes glucose and causes weight loss by acting on brain circuits that regulate energy and metabolism. In obese, diabetic mice, ENT-03 rapidly lowers blood glucose, reduces food intake and adiposity, eliminates liver fat, and improves liver function. This study compared ENT-03 to semaglutide, a combination of the two compounds, and vehicle in Diet Induced Obesity (DIO) mice. While the vehicle-treated mice gained weight through the duration of the study, mice treated with ENT-03, Semaglutide, or a combination of the two drugs all lost weight and reduced insulin and glucose levels. ENT-03 showed a greater reduction in weight than Semaglutide over the 10-week treatment period. Additive weigh loss was seen when the drugs were used in combination. After cessation of therapy, weight loss and reduction in glucose and insulin were sustained for an additional two months in the ENT-03 treated mice but not Semaglutide treated mice. In addition, ENT-03 showed substantially greater preservation of lean mass in comparison to other treatment groups. 'GLP-1 agonists have revolutionized the treatment of obesity and type 2 diabetes,' said Richard Larson, MD, PhD. 'However, their impressive efficacy comes at the price of tolerability challenges, the loss of lean body mass, and the need to remain on treatment to sustain weight loss. ENT-03 represents a novel drug candidate that could be an alternative treatment to GLP-1 agonists or used in combination with them. We believe that ENT-03 could have a substantial impact on the obesity drug market since it has potential benefits beyond weight loss.' Metabolics Pharma has completed a Phase 1a, first in human, randomized, double-blind, single ascending dose study of ENT-03. Results of the Phase 1a trial were presented at the American Diabetes Association 85 th Scientific Sessions on June 22, 2025. A Phase 1b clinical trial is planned to initiate in the second half of 2025. About Metabolics Pharma Metabolics Pharma develops novel therapies for the treatment of metabolic diseases including obesity and type 2 diabetes. The Company's lead compound, ENT-03, in development for the treatment of type 2 diabetes and obesity, increases insulin sensitivity by acting at the level of the brain. ENT-03 has completed a Phase 1a clinical trial and will begin a Phase 1b clinical trial in the second half of 2025. For more information, please visit

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store